International Journal of Colorectal Disease

, Volume 34, Issue 11, pp 1971–1978 | Cite as

A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort

  • Raunak Jay SomanEmail author
  • Malisetty Venkat Swamy
Original Article



This prospective, randomized, double-blind, placebo-controlled, parallel-group study aimed to determine the efficacy and safety of a multistrain (Bacillus coagulans [SNZ 1969], Bacillus clausii [SNZ 1971], and Bacillus subtilis [SNZ 1972]) probiotic blend (SNZ TriBac) in managing symptoms of gastrointestinal (GI) discomfort in the absence of specific pathologies.


Sixty adults with symptoms of GI discomfort were enrolled (mean age, 34.89 ± 9.95 years) and randomized to receive either SNZ TriBac or placebo. Changes from baseline in Severity of Dyspepsia Assessment (SODA), Gastrointestinal Symptom Rating Scale (GSRS), and Quality of Life (QoL) scales over the course of product use were determined at baseline and on days 30 and 37 as study outcomes.


On day 30, significant improvement with SNZ TriBac was noted in SODA burping/belching (P = 0.025), bloating (P = 0.048), sour taste (P = 0.025), and total (P = 0.007) scores as well as pain (P = 0.003), non-pain (P = 0.04), and satisfaction (P = 0.03) subscores. Significant improvement with SNZ TriBac was also observed in SODA burping/belching (P = 0.011), sour taste (P = 0.011), and total SODA scores (P < 0.001), and in SODA pain (P = 0.005), non-pain (P = 0.06), and satisfaction (P = 0.004) subscores on day 37. No adverse events were reported.


Significant improvement in final SODA scores and subscores with SNZ TriBac versus placebo indicates improvement in several symptoms of gastrointestinal discomfort. This multistrain probiotic blend was well tolerated and could be an effective option for treatment of GI discomfort.

Trial registration

Clinical Trials Registry of India (CTRI/2018/05/014071)


Gastrointestinal discomfort Probiotic Bacillus coagulans Bacillus clausii Bacillus subtilis 



The authors would like to thank JCDC, Pune, for conducting and analyzing the data of this study and CBCC Global Research for providing medical writing assistance for development of  this manuscript.

Authors’ contributions

All authors made substantial contributions to study conception, acquisition of data, and preparation of this manuscript. All authors read and approved the final version of this manuscript.

Funding information

The study was funded by Sanzyme Biologics Pvt. Ltd., India.

Compliance with ethical standards

Before participation in the study, all subjects provided written informed consent. This study was performed in compliance with International Conference on Harmonisation (ICH E6[R2]) “Guidance on Good Clinical Practice,” Declaration of Helsinki; Indian Good Clinical Practices Guideline; National Ethical Guidelines for Biomedical and Health Research involving human participants, Indian Council of Medical Research 2017; and, relevant standard operating protocols of Jehangir Clinical Development Centre, Pune, Maharashtra, India. This study was approved by the institutional review board of Jehangir Clinical Development Centre, Pune, Maharashtra, India, and was registered in the Clinical Trials Registry of India (CTRI/2018/05/014071).

Conflict of interest

R J Soman and M V Swamy are employees of Sanzyme Biologics Pvt Ltd. The authors have no other conflict of interest to declare with respect to this authored publication.


  1. 1.
    Hall EH, Crowe SE (2011) Environmental and lifestyle influences on disorders of the large and small intestine: implications for treatment. Dig Dis 29:249–254. CrossRefPubMedGoogle Scholar
  2. 2.
    Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI (2005) Host-bacterial mutualism in the human intestine. Science 307:1915–1920. CrossRefPubMedGoogle Scholar
  3. 3.
    Clemente JC, Ursell LK, Parfrey LW, Knight R (2012) The impact of the gut microbiota on human health: an integrative view. Cell 148:1258–1270. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Moles L, Gomez M, Heilig H et al (2013) Bacterial diversity in meconium of preterm neonates and evolution of their fecal microbiota during the first month of life. PLoS One 8:e66986. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cresci GA, Bawden E (2015) Gut microbiome: what we do and don’t know. Nutr Clin Pract 30:734–746. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO (2007) Development of the human infant intestinal microbiota. PLoS Biol 5:e177. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Morelli L (2008) Postnatal development of intestinal microflora as influenced by infant nutrition. J Nutr 138:1791S–1795S. CrossRefPubMedGoogle Scholar
  8. 8.
    Morowitz MJ, Denef VJ, Costello EK et al (2011) Strain-resolved community genomic analysis of gut microbial colonization in a premature infant. Proc Natl Acad Sci U S A 108:1128–1133. CrossRefPubMedGoogle Scholar
  9. 9.
    Schwartz S, Friedberg I, Ivanov IV, Davidson LA, Goldsby JS, Dahl DB, Herman D, Wang M, Donovan SM, Chapkin RS (2012) A metagenomic study of diet-dependent interaction between gut microbiota and host in infants reveals differences in immune response. Genome Biol 13:r32. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Simren M, Mansson A, Langkilde AM et al (2001) Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 63:108–115. CrossRefPubMedGoogle Scholar
  11. 11.
    Miwa H (2012) Life style in persons with functional gastrointestinal disorders--large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil 24(464-471):e217. CrossRefGoogle Scholar
  12. 12.
    Córdoba AF and AO of the UN and WHO (2001) Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria
  13. 13.
    Staudacher HM, Whelan K (2016) Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc Nutr Soc 75:306–318. CrossRefPubMedGoogle Scholar
  14. 14.
    Elshaghabee FMF, Rokana N, Gulhane RD, Sharma C, Panwar H (2017) Bacillus as potential probiotics: status, concerns, and future perspectives. Front Microbiol 8:1490. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Igarashi M, Nakae H, Matsuoka T, Takahashi S, Hisada T, Tomita J, Koga Y (2017) Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. BMJ Open Gastroenterol 4:e000144. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rabeneck L, Cook KF, Wristers K, Souchek J, Menke T, Wray NP (2001) SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 54:755–765CrossRefGoogle Scholar
  17. 17.
    Nakae H, Tsuda A, Matsuoka T, Mine T, Koga Y (2016) Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt. BMJ Open Gastroenterol 3:e000109. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR (2009) A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 9:85. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hun L (2009) Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 121(2):119–124CrossRefGoogle Scholar
  20. 20.
    Rogha M, Esfahani MZ, Zargarzadeh AH (2014) The efficacy of a synbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 7(3):156–163PubMedPubMedCentralGoogle Scholar
  21. 21.
    Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D (2015) Role of the normal gut microbiota. World J Gastroenterol 21:8787–8803. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J (2018) A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther 35:289–310. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rijkers GT, de Vos WM, Brummer R-J, Morelli L, Corthier G, Marteau P (2011) Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr 106:1291–1296. CrossRefPubMedGoogle Scholar
  24. 24.
    Hempel S, Newberry S, Ruelaz A et al (2011) Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 200:1–645Google Scholar
  25. 25.
    Wilkins T, Sequoia J (2017) Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician 96:170–178PubMedGoogle Scholar
  26. 26.
    Svedlund J, Sjodin I, Dotevall G (1988) GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33:129–134. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Sanzyme Biologics Pvt. Ltd.HyderabadIndia

Personalised recommendations